Cargando…

Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin

Diabetic ketoacidosis is a leading cause of morbidity and mortality in diabetic patients, and its diagnosis should be timely and accurate. SGLT2 inhibitors are a new class of antidiabetic medications that increase the renal excretion of glucose. It is thought that increased urinary excretion of gluc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sexe, Jordan, Mayes, Chadwick, Tofts, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350083/
https://www.ncbi.nlm.nih.gov/pubmed/32695525
http://dx.doi.org/10.1155/2020/7437892
_version_ 1783557201708711936
author Sexe, Jordan
Mayes, Chadwick
Tofts, Peter
author_facet Sexe, Jordan
Mayes, Chadwick
Tofts, Peter
author_sort Sexe, Jordan
collection PubMed
description Diabetic ketoacidosis is a leading cause of morbidity and mortality in diabetic patients, and its diagnosis should be timely and accurate. SGLT2 inhibitors are a new class of antidiabetic medications that increase the renal excretion of glucose. It is thought that increased urinary excretion of glucose will mask hyperglycemia during DKA. This can lead to a delayed diagnosis of DKA and worsen outcomes. In this report, we detail a case of euglycemic DKA in a patient who presented to the Emergency Department meeting criteria for septic shock.
format Online
Article
Text
id pubmed-7350083
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-73500832020-07-20 Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin Sexe, Jordan Mayes, Chadwick Tofts, Peter Case Rep Crit Care Case Report Diabetic ketoacidosis is a leading cause of morbidity and mortality in diabetic patients, and its diagnosis should be timely and accurate. SGLT2 inhibitors are a new class of antidiabetic medications that increase the renal excretion of glucose. It is thought that increased urinary excretion of glucose will mask hyperglycemia during DKA. This can lead to a delayed diagnosis of DKA and worsen outcomes. In this report, we detail a case of euglycemic DKA in a patient who presented to the Emergency Department meeting criteria for septic shock. Hindawi 2020-06-30 /pmc/articles/PMC7350083/ /pubmed/32695525 http://dx.doi.org/10.1155/2020/7437892 Text en Copyright © 2020 Jordan Sexe et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Sexe, Jordan
Mayes, Chadwick
Tofts, Peter
Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin
title Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin
title_full Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin
title_fullStr Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin
title_full_unstemmed Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin
title_short Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin
title_sort euglycemic diabetic ketoacidosis in a lung cancer patient using empagliflozin
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350083/
https://www.ncbi.nlm.nih.gov/pubmed/32695525
http://dx.doi.org/10.1155/2020/7437892
work_keys_str_mv AT sexejordan euglycemicdiabeticketoacidosisinalungcancerpatientusingempagliflozin
AT mayeschadwick euglycemicdiabeticketoacidosisinalungcancerpatientusingempagliflozin
AT toftspeter euglycemicdiabeticketoacidosisinalungcancerpatientusingempagliflozin